Early Trial Shows Stem Cell Therapy May Reduce Insulin Dependence in Type 1 Diabetes

Zimislecel is an allogeneic stem cell-derived islet cell therapy—meaning it's made from donated stem cells that have been grown into insulin-producing islet cells in a laboratory. Type 1 diabetes occurs when the immune system mistakenly attacks and destroys a person's own islet cells, making them unable to produce insulin. Zimislecel aims to replace those lost cells by transplanting new ones into the body.

The therapy combines cell transplantation with immunosuppressive medications that help prevent the immune system from attacking the new cells, much like patients who receive organ transplants require.

Researchers tested zimislecel in 14 people with Type 1 diabetes who had no detectable insulin production at baseline. Two participants received a lower dose, while 12 received a full dose of 0.8 billion cells. All participants took glucocorticoid-free immunosuppressive therapy to protect the transplanted cells.

Among the 12 participants who received the full dose, striking results emerged at the one-year mark: 83% no longer required insulin injections. All full-dose recipients remained free of severe low-blood-sugar events and achieved their blood sugar targets, spending more than 70% of their time in the healthy glucose range of 70–180 mg/dL.

A key indicator of success was the detection of C-peptide, a marker that shows new islet cells were surviving and functioning. All 14 participants—including the two who received the lower dose—showed evidence of islet cell engraftment and activity after treatment.

These findings are encouraging because they suggest that stem cell-derived islet transplantation could one day reduce or eliminate insulin dependence for people with Type 1 diabetes. Reducing insulin injections and severe low-blood-sugar events would meaningfully improve quality of life for many patients.

However, this was an early-stage, small trial. The results do not yet confirm that zimislecel is safe or effective for all people with Type 1 diabetes. Researchers must conduct larger trials to understand whether the benefits persist beyond one year, how long the transplanted cells survive, and what long-term effects the immunosuppressive medications may have.

This work represents meaningful progress in regenerative medicine for Type 1 diabetes, but patients and families should understand that zimislecel is not yet available outside of clinical trials and remains years away from potential regulatory approval.

Origin: European Medical Journal (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.